Effective Date: January 1, 2026

Policy Statement: Bileomix Inc. (the “Company”) is committed to fostering innovative research collaborations with academic institutions to advance scientific discovery in fields such as gut health, microbiome analysis, and personalized nutrition. To promote efficient use of resources and maximize the impact of limited funding, the Company has established this policy limiting indirect costs (IDC, also known as facilities and administrative costs or overhead) for qualifying academic grantees.

Scope: This policy applies to all industry-sponsored research agreements where Bileomix Inc. acts as the sponsor and the recipient is an accredited academic institution or university. It covers projects focused on basic or applied research, including but not limited to clinical trials, analytical services, and collaborative studies utilizing Company technologies (e.g., S’Wipe gut health tests).

Indirect Cost Limitation: For all qualifying projects with total direct costs under $50,000, the Company will not reimburse indirect costs, setting the IDC rate at 0%. This limitation ensures that funds are directed primarily toward direct research expenses, such as personnel, materials, participant support, and analytical services, without additional overhead burdens.

Qualifying projects must:

• Be non-commercial in nature (e.g., aimed at generating publishable data or proof-of-concept results).
• Involve mutual scientific benefits, such as co-authorship opportunities or shared intellectual property rights as defined in the agreement.
• Comply with all applicable laws, regulations, and ethical standards, including IRB approvals for human subjects research.

For projects exceeding $50,000 in direct costs, IDC rates may be negotiated on a case-by-case basis, not to exceed 20% of modified total direct costs (MTDC), in alignment with federal guidelines where applicable.

Rationale:

• Resource Efficiency: By waiving or limiting IDC, the Company enables academic partners to allocate more resources to core research activities, accelerating innovation and outcomes.
• Mutual Benefit: This approach strengthens long-term partnerships, facilitating joint publications, grant applications, and future collaborations.
• Consistency: The policy is applied uniformly to all academic grantees to ensure fairness and transparency.

Implementation:

• This policy will be referenced in all relevant sponsored research agreements.
• Academic partners may request confirmation of this policy during budget negotiations.
• The Company reserves the right to audit project expenditures to ensure compliance with direct cost usage.

Contact: For questions or to discuss applicability, contact: Alexey Melnik, CEO Bileomix Inc. Email: info@bileomix.com

This policy is publicly available on the Company’s website and may be updated periodically. All changes will be posted with an effective date.